Loading stock data…
$0.21-0.01 (-2.44%)
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
TScan Therapeutics, Inc. in the Healthcare sector is trading at $0.21 with a market capitalization of $16M. Wall Street consensus targets $1.00 (2 analysts), implying a +373.0% move over the next 12 months. The stock is currently near its 52-week low of $0.20, remaining 76.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.05M↑ | $982,000↓ | $2.57M↑ | $2.51M↓ | $3.08M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.49M↓ | -$29.14M↓ | -$23.86M↑ | -$37.05M↑ | -$38.65M |
| Net Income | -$30.36M↓ | -$28.67M↓ | -$22.98M↑ | -$35.71M↑ | -$36.95M |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of...